Advancing 90-day mortality and anastomotic leakage predictions after oesophagectomy for cancer using explainable AI (XAI) - Djerf, Sebastian; Akesson, Oscar; Nilsson, Magnus; Lindblad, Mats; Hedberg, Jakob; Johansson, Jan; Frigyesi, Attila (medRxiv, 2024)
Oesophagectomy for cancer of the oesophagus carries significant morbidity and mortality. Ninety-day mortality and anastomosis leakage are critical early postoperative problems traditionally analysed through logistic regression. In this study, we challenge traditional logistic regression models to predict results with new explainable AI (XAI) models. We used the Swedish National Quality Register for Oesophageal and Gastric Cancer (NREV) to perform traditional multivariable logistic regression and XAI. The 90-day mortality was 6.0%, while anastomosis leakage was present in 12.4%. The XAI models yielded an area under the curve (AUC) of 0.91 for 90-day mortality (as compared with 0.84 for logistic regression). For anastomosis leakage, the AUC was 0.84 using XAI (0.74 using logistic regression). We show that age (mortality increases sharply after 55 years) and body mass index (BMI) (lowest mortality for BMI 30 kg/m2) are important survival factors. Additionally, we show that surgery time (minimum anastomosis leakage for a surgery time of 200 min to sharply increase to a maximum at 375 min) and BMI (the lower the BMI, the less anastomosis leakage) are important factors for anastomosis leakage. The surgical understanding of anastomosis leakage and mortality after oesophagectomy is advanced by judiciously applying XAI to structured data. Our nationwide oesophagectomy data contains significant nonlinear relationships. With the help of XAI, we extract personalised knowledge, bringing oesophagus surgery one step closer to personalised medicine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthor Attila Frigyesi received: Regional research support, Region Skane #2022-1284; Governmental funding of clinical research within the Swedish National Health Service (ALF) #2022:YF0009 and #2022-0075; Crafoord Foundation grant number #2021-0833; Lions Skane research grants; Skane University Hospital grants; Swedish Heart and Lund Foundation (HLF) #2022-0352 and #2022-0458.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Regional Ethical Board of Stockholm gave ethical approval for this work, Dnr 2013/596 31/3, amendment 2020-06495I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript